I'm going to keep buying as long as I have cash. I think a lot of people will find out about QSAM pretty soon.

How many shares does everyone own? I own 50,000.

I'm here because the company's IR got me in at $0.50. I met him 10 years ago on a mining stock and have been involved with 8 or 10 stocks he gave me over the years. He introduced me to QSAM.

Why pay for IR when the results are this pathetic? BTTR went from $9 when this was announced to $3.81. Six figures wasted. https://www.globenewswire.com/en/news-release/2021/02/17/2177528/0/en/Better-Choice-Company-Retains-Emerging-Markets-Consulting-LLC-EMC-and-Winning-Media-to-Provide-Investor-Public-Relations-Services.html

No one has any stock. Market makers trying to keep it down.

I don't know for sure, but I talked to the investor relations department and it sounds like there might be 200,000 to 300,000. After they are gone I think QSAM goes back above $1.

According to SEC filings maybe 500,000 shares. Looks like it was all purchased around $.25

No, because there are a handful of idiots who have cheap stock. Once they arre out of the way the stock will perform much better.

Wooohooo! QSAM is in Phase 1 with the FDA! The valuation just went up! https://finance.yahoo.com/news/qsam-biosciences-announces-fda-clearance-130000396.html

Long WISH and looking for the run back to $10. Coming soon.

No dillution. The stock looks good.

I like the management team and board of directors. They just updated OTC Markets. They aren't small potatoes. https://www.otcmarkets.com/stock/CWNRD/profile

I like the management team and board of directors. They just updated OTC Markets. They aren't small potatoes. https://www.otcmarkets.com/stock/CWNRD/profile

QLGN time to load

Next leg up starting

There is no Yuen Wong

Scam alert! NSAV

Not an LOI. Definitive agreement.

I talked to IR and he said they could have done a bigger reverse, but they wanted to give shareholders a chance to have a decent number of shares.

1 for 15 makes the company more attractive. Look at the filings with the SEC and there haven't been hardly any new shares come into the market. I bought more at $0.0024, I'm hearing there is big news coming.

I'm here for the coming pump.

I took your advice and reached out to him. He said QSAM filed the IND a week before the PR came out, so they could be in Phase 1 next week. He also said "Cyclosam is the same drug as Lantheus' (NASDAQ: LNTH) FDA approved drug, Quadramet. QSAM filed its IND on Cyclosam for the treatment of bone cancer. Lantheus has FDA approval for the drug as a pain treatment for cancer patients." The two guys who's pictures are at the bottom of the management profile are the inventors. It sounds like QSAM and CycloSam could benefit kids with bone cancer.

It looks like there are one or two small time sellers. I've been able to buy some stock on the bid.

Whoa! QSAM Biosciences Announces Submission of IND Application for CycloSam® with FDA

I wasn't expecting this? QSAM is for real. From the FDA's web site "Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk."

https://finance.yahoo.com/news/qsam-biosciences-announces-submission-ind-130000188.html

I'm very optimistic near-term. Even more optimistic longer term.

Time to load up here at $0.40.

So, QLGN cancelled this EUA that was going nowhere and all of the rookies from Reddit panicked and sold after hours Friday. They have been whining about the EUA for over a month. If the stock is weak on Monday's open, I'm adding to my position. I got in at $3.27 and out at $4.35. Back in again around $2.80, but looking to add on any weakness.

So don't buy the stock? If you really think it's garbage, short it. I like the way the company management looks. I've also taken my original investment off of the table and I'm going to let the rest ride.

Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL

https://finance.yahoo.com/news/qualigen-therapeutics-secures-option-negotiate-133000454.html

Life Clips, Inc. announced Wednesday it entered into a letter of intent to acquire Cognitive Apps Software Solutions Inc. (Cognitive apps), a developer of artificial intelligence (AI) applications for the healthcare industry and psychedelic research that uses speech-based technology to identify at risk groups before the onset of clinically significant symptoms. Life Clips shares rose above $0.01 and traded an impressive 485 million shares for the day on the news. Cognitive Apps provides an AI powered mental health analytics platform empowering businesses to measure, understand, and improve mental well-being of their employees, patients or customers with easy to use tools. The Cognitive Apps assessment is fast and easy to administer, and the patient only needs to record their voice on a handset, iPad, or tablet. The Cognitive Apps assessment is designed to be administered as often as monthly, in order to provide a more granular picture of changes in mental health over time. As a result, the Cognitive apps assessment can be routinely completed to monitor mental health and track variables that might be impacted by treatment.

Dr. Manideep Gopishetty, CEO and Co-founder of Cognitive Apps, said, "Our advanced voice recognition AI technology diagnostic core can identify various mental health disorders. This is especially beneficial in the corporate environment in order to ascertain corporate employees’ mental wellness and to provide personalized remote mental health care." Dr. Gopishetty continued, "Our technology can also be beneficial in clinical intelligence diagnostic and monitoring solutions for hospitals and clinics. Our goal is to use advanced AI based technology to disrupt industries such as healthcare, mental health, and both clinical and academic psychedelic research."

With the acquisition, Life Clips gains access to Cognitive Apps' intellectual property, including AI enabled speech-based technology, and its research and development team. Life Clips will further develop Cognitive Apps' technology for use in the development and testing of psychedelics for the treatment of various mental health disorders. Cognitive Apps delivers a comprehensive approach to well-being, supporting the whole person. Cognitive apps currently has partnerships with Ehave, Mycotopia, Biomedican, Welmind EMR, Betterhelp, Belshare, and Movefit.

https://finance.yahoo.com/news/psychedelic-stocks-poised-resume-upward-133000028.html

Life Clips in mainstream article on psychedelic stocks today. Mentioned with MindMed, Compass Pathways, Ehave, and Mydecine.

https://finance.yahoo.com/news/psychedelic-stocks-poised-resume-upward-133000028.html

I think mkt makers are short. .02 or .03 coming quick, if there is news.

Thanks for the great post that is spot on. Looking at the officers and directors of QSAM, it looks more like a NASDAQ biotech than an OTC. There is not one company in FDA Phase 1 with less than a $50 million market cap. QSAM is about $12 million. Doug Baum said publicly the Company hopes to be in FDA Phase 1 trials the first half of 2021. I'm not selling any either.

We could use some news! I'm still long QLGN.

I'm going to go with Dr. Link over someone fraudulently using the ex-owner of the Oakland A's name. Let's look at Dr; Link's abbreviated bio again:

"Dr. Link brings decades of biotech and drug development experience to QSAM. He currently serves on the executive committee of the Board of Directors at NovaScan Inc., a clinical-stage company focused on cancer detection; and is the founder and President of biotech startup Syncromune. Previously, Dr. Link was the CEO, CSO, Chairman, and founder of NewLink Genetics, a NASDAQ-listed immunotherapy company focused on developing novel immuno-oncology product candidates.

During his tenure at NewLink, Dr. Link led a series of collaborative transactions totaling hundreds of millions of dollars with Merck, Roche and the United States government. He also oversaw the collaboration with Merck to develop EVERBO, the first Ebola vaccine to receive FDA approval.

Prior to founding NewLink Genetics, Dr. Link was an attending physician at the National Cancer Institute. He has authored more than 150 peer-reviewed papers. He previously received funding from the National Institute of Health, the National Cancer Institute, the American Cancer Society, and others. Dr. Link received an M.D. from Stanford University, and he attended the Air Force Academy."

What makes you think four or five positive posts over the course of a few weeks are "a significant volume?"

I agree with you. QSAM's management team is more like a larger NASDAQ biopharma company. https://qsambio.com/#leadership

Great trade, man. I'm long since $0.28.

Plus, QLGN has great management. Check out ichael Poirier's presentation at the H.C. Wainwright Bioconnect 2021 Conference last month. https://journey.ct.events/view/52bd06f2-13c4-4ad4-9772-90191e3a938a

Name and symbol change. Getting in the synthetic psilocybin business. https://finance.yahoo.com/news/mycotopia-therapies-20-20-global-133000264.html